Differential effects of leucine and methionine enkephalin on morphine- induced analgesia, acute tolerance and dependence

JL Vaught and AE Takemori

Intracerebroventricular (40-80 microgram) or i.p. (5-20 mg/kg) injection of leucine enkephalin 15 min before or after s.c. morphine administration resulted in a marked, dose-dependent enhancement of morphine analgesia as measured by the mouse tail-flick assay. Further, i.p. injection of leucine enkephalin (5 mg/kg) enhanced the analgesia produced by methadone and levorphanol in the tail-flick assay but not that by nalorphine in the abdominal constriction assay. Met- but not leu-enkephalin was an active analgesic in the abdominal constriction assay with the doses used. (D-Ala2, D-leu5)-enkephalin (1 mg/kg) treatment also markedly enhanced morphine analgesia. Similarly, administration of leucine enkephalin enhanced the development of acute tolerance and dependence produced by a single dose of morphine. Methionine enkephalin had no effect on any of the pharmacological responses produced by morphine, methadone or levorphanol. Morphine brain levels of mice after treatment with leucine or methionine enkephalin were found to be no different than those of saline-treated control animals. These results suggest that leucine enkephalin may be an important and potent physiological modulator of narcotic efficacy.

Volume 208, Issue 1, pp. 86-90, 01/01/1979
Copyright © 1979 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				G. P. Do Carmo, R. Polt, E. J. Bilsky, K. C. Rice, and S. S. Negus Behavioral Pharmacology of the {micro}/{delta} Opioid Glycopeptide MMP2200 in Rhesus Monkeys J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 939 - 948. [Abstract] [Full Text] [PDF]

				A. Dahan, B. Kest, A. R. Waxman, and E. Sarton Sex-Specific Responses to Opiates: Animal and Human Studies Anesth. Analg., July 1, 2008; 107(1): 83 - 95. [Abstract] [Full Text] [PDF]

				M. R. Bruchas, B. B. Land, M. Aita, M. Xu, S. K. Barot, S. Li, and C. Chavkin Stress-Induced p38 Mitogen-Activated Protein Kinase Activation Mediates {kappa}-Opioid-Dependent Dysphoria J. Neurosci., October 24, 2007; 27(43): 11614 - 11623. [Abstract] [Full Text] [PDF]

				D. J. Daniels, N. R. Lenard, C. L. Etienne, P.-Y. Law, S. C. Roerig, and P. S. Portoghese Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series PNAS, December 27, 2005; 102(52): 19208 - 19213. [Abstract] [Full Text] [PDF]

				S. Roy, X. Guo, J. Kelschenbach, Y. Liu, and H. H. Loh In Vivo Activation of a Mutant {micro}-Opioid Receptor by Naltrexone Produces a Potent Analgesic Effect But No Tolerance: Role of {micro}-Receptor Activation and {delta}-Receptor Blockade in Morphine Tolerance J. Neurosci., March 23, 2005; 25(12): 3229 - 3233. [Abstract] [Full Text] [PDF]

				J. P. McLaughlin, L. C. Myers, P. E. Zarek, M. G. Caron, R. J. Lefkowitz, T. A. Czyzyk, J. E. Pintar, and C. Chavkin Prolonged Kappa Opioid Receptor Phosphorylation Mediated by G-protein Receptor Kinase Underlies Sustained Analgesic Tolerance J. Biol. Chem., January 16, 2004; 279(3): 1810 - 1818. [Abstract] [Full Text] [PDF]

				G. W. Stevenson, J. E. Folk, D. C. Linsenmayer, K. C. Rice, and S. S. Negus Opioid Interactions in Rhesus Monkeys: Effects of {delta} + {micro} and {delta} + {kappa} Agonists on Schedule-Controlled Responding and Thermal Nociception J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 1054 - 1064. [Abstract] [Full Text] [PDF]

				J. P. McLaughlin, M. Marton-Popovici, and C. Chavkin {kappa} Opioid Receptor Antagonism and Prodynorphin Gene Disruption Block Stress-Induced Behavioral Responses J. Neurosci., July 2, 2003; 23(13): 5674 - 5683. [Abstract] [Full Text] [PDF]

				R. J. Tallarida Drug Synergism: Its Detection and Applications J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 865 - 872. [Abstract] [Full Text]

				J. J. Rady, B. B. Holmes, L. F. Tseng, and J. M. Fujimoto Inverse Agonist Action of Leu-Enkephalin at delta 2-Opioid Receptors Mediates Spinal Antianalgesia J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 582 - 589. [Abstract] [Full Text]

				R. W. Hurley and D. L. Hammond Contribution of Endogenous Enkephalins to the Enhanced Analgesic Effects of Supraspinal {micro} Opioid Receptor Agonists after Inflammatory Injury J. Neurosci., April 1, 2001; 21(7): 2536 - 2545. [Abstract] [Full Text] [PDF]

				B. Kest, S. G. Wilson, and J. S. Mogil Sex Differences in Supraspinal Morphine Analgesia Are Dependent on Genotype J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1370 - 1375. [Abstract] [Full Text]

				J. P. McLaughlin, K. P. Hill, Q. Jiang, A. Sebastian, S. Archer, and J. M. Bidlack Nitrocinnamoyl and Chlorocinnamoyl Derivatives of Dihydrocodeinone: In Vivo and In Vitro Characterization of µ-Selective Agonist and Antagonist Activity J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 304 - 311. [Abstract] [Full Text]

				J. Y. Xu, K. P. Hill, and J. M. Bidlack The Nitric Oxide/Cyclic GMP System at the Supraspinal Site Is Involved in the Development of Acute Morphine Antinociceptive Tolerance, J. Pharmacol. Exp. Ther., January 1, 1998; 284(1): 196 - 201. [Abstract] [Full Text]

				S. J. O'Neill, M. A. Collins, H. O. Pettit, R. W. McNutt, and K.-J. Chang Antagonistic Modulation Between the Delta Opioid Agonist BW373U86 and the Mu Opioid Agonist Fentanyl in Mice J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 271 - 277. [Abstract] [Full Text]